Limits...
Effects of Hyul-Bu-Chuke-Tang on Erythrocyte Deformability and Cerebrovascular CO(2) Reactivity in Normal Subjects.

Jung WS, Park JY, Byeon HS, Kim YJ, Park JM, Park SU, Cho SY, Moon SK - Evid Based Complement Alternat Med (2012)

Bottom Line: HCEt significantly improved the CVR 2 hours after administration compared to the historical control group (9.1 ± 4.0% versus -8.1 ± 4.1%, P = 0.007).The mean blood pressure and pulse rate did not vary from baseline values in either group.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular and Neurologic Diseases, College of Korean Medicine, Kyung Hee University, Seoul 130-702, Republic of Korea.

ABSTRACT
Aim. Hyul-bu-chuke-tang (HCEt) is a well-known traditional herbal medicine that is used for the treatment of ischemic cerebrovascular disorders. We investigated the acute effects of HCEt on erythrocyte deformability and cerebrovascular CO(2) reactivity (CVR) in healthy male subjects. Materials and Methods. We examined erythrocyte deformability in an HCEt group (n = 14) and a control group (n = 10). CVR was measured using hyperventilation-induced CO(2) reactivity of the middle cerebral artery and transcranial Doppler (TCD) in the HCEt group (n = 11). A historical control group (n = 10) of CVR measurements was also created from our previous study. All measurements were performed prior to and 1, 2, and 3 hours after HCEt administration. Results. HCEt significantly improved erythrocyte deformability 1 hour after administration compared to the control group (2.9 ± 1.1% versus -0.6 ± 1.0%, P = 0.034). HCEt significantly improved the CVR 2 hours after administration compared to the historical control group (9.1 ± 4.0% versus -8.1 ± 4.1%, P = 0.007). The mean blood pressure and pulse rate did not vary from baseline values in either group. Conclusions. We demonstrated that HCEt improved erythrocyte deformability and CVR. Our findings suggest that an improvement in erythrocyte deformability contributes to HCEt's effect on cerebral microcirculation.

No MeSH data available.


Related in: MedlinePlus

Change of cerebrovascular CO2 reactivity (CVR) in the HCEt group (n = 11) at each time point. aFor comparison, CVR data are also shown for historical control group of 10 healthy young male subjects matched with for age and who received placebo. All values are the percent change compared to baseline. The vertical bars represent the means ± S.E.M. The P values were obtained from independent t-test. HCEt: hyul-bu-chuke-tang; h: hour. #P < 0.05 compared to the historical control group.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3368491&req=5

fig2: Change of cerebrovascular CO2 reactivity (CVR) in the HCEt group (n = 11) at each time point. aFor comparison, CVR data are also shown for historical control group of 10 healthy young male subjects matched with for age and who received placebo. All values are the percent change compared to baseline. The vertical bars represent the means ± S.E.M. The P values were obtained from independent t-test. HCEt: hyul-bu-chuke-tang; h: hour. #P < 0.05 compared to the historical control group.

Mentions: We also confirmed a 9.1% increase in CVR for 2 hours after HCEt administration, which was significant compared to baseline (Figure 2). This result suggests that HCEt increased regional resting cerebral blood flow. CVR is the change in cerebral blood flow velocity in response to changes in PCO2, and it is a reliable index of relative changes in cerebral blood flow [17–20]. Cerebrovascular CO2 reactivity (CVR) reflects the consequent response of arterioles in the cerebral vascular bed to the dilatory CO2 stimulus [13]. Ackerman demonstrated that CVR is proportional to the regional resting blood flow/blood pressure ratio and determined this ratio as conductance (i.e., the reciprocal of cerebrovascular resistance) [17, 20]. We continuously monitored blood pressure and heart rate during CVR examinations and confirmed that these values were constant (Table 2). Therefore, increases in CVR after HCEt administration were proportional to the increase in regional resting blood flow [20, 21]. We postulated that HCEt increased regional resting blood flow as a result of reduced cerebral microcirculatory resistance.


Effects of Hyul-Bu-Chuke-Tang on Erythrocyte Deformability and Cerebrovascular CO(2) Reactivity in Normal Subjects.

Jung WS, Park JY, Byeon HS, Kim YJ, Park JM, Park SU, Cho SY, Moon SK - Evid Based Complement Alternat Med (2012)

Change of cerebrovascular CO2 reactivity (CVR) in the HCEt group (n = 11) at each time point. aFor comparison, CVR data are also shown for historical control group of 10 healthy young male subjects matched with for age and who received placebo. All values are the percent change compared to baseline. The vertical bars represent the means ± S.E.M. The P values were obtained from independent t-test. HCEt: hyul-bu-chuke-tang; h: hour. #P < 0.05 compared to the historical control group.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3368491&req=5

fig2: Change of cerebrovascular CO2 reactivity (CVR) in the HCEt group (n = 11) at each time point. aFor comparison, CVR data are also shown for historical control group of 10 healthy young male subjects matched with for age and who received placebo. All values are the percent change compared to baseline. The vertical bars represent the means ± S.E.M. The P values were obtained from independent t-test. HCEt: hyul-bu-chuke-tang; h: hour. #P < 0.05 compared to the historical control group.
Mentions: We also confirmed a 9.1% increase in CVR for 2 hours after HCEt administration, which was significant compared to baseline (Figure 2). This result suggests that HCEt increased regional resting cerebral blood flow. CVR is the change in cerebral blood flow velocity in response to changes in PCO2, and it is a reliable index of relative changes in cerebral blood flow [17–20]. Cerebrovascular CO2 reactivity (CVR) reflects the consequent response of arterioles in the cerebral vascular bed to the dilatory CO2 stimulus [13]. Ackerman demonstrated that CVR is proportional to the regional resting blood flow/blood pressure ratio and determined this ratio as conductance (i.e., the reciprocal of cerebrovascular resistance) [17, 20]. We continuously monitored blood pressure and heart rate during CVR examinations and confirmed that these values were constant (Table 2). Therefore, increases in CVR after HCEt administration were proportional to the increase in regional resting blood flow [20, 21]. We postulated that HCEt increased regional resting blood flow as a result of reduced cerebral microcirculatory resistance.

Bottom Line: HCEt significantly improved the CVR 2 hours after administration compared to the historical control group (9.1 ± 4.0% versus -8.1 ± 4.1%, P = 0.007).The mean blood pressure and pulse rate did not vary from baseline values in either group.Conclusions.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular and Neurologic Diseases, College of Korean Medicine, Kyung Hee University, Seoul 130-702, Republic of Korea.

ABSTRACT
Aim. Hyul-bu-chuke-tang (HCEt) is a well-known traditional herbal medicine that is used for the treatment of ischemic cerebrovascular disorders. We investigated the acute effects of HCEt on erythrocyte deformability and cerebrovascular CO(2) reactivity (CVR) in healthy male subjects. Materials and Methods. We examined erythrocyte deformability in an HCEt group (n = 14) and a control group (n = 10). CVR was measured using hyperventilation-induced CO(2) reactivity of the middle cerebral artery and transcranial Doppler (TCD) in the HCEt group (n = 11). A historical control group (n = 10) of CVR measurements was also created from our previous study. All measurements were performed prior to and 1, 2, and 3 hours after HCEt administration. Results. HCEt significantly improved erythrocyte deformability 1 hour after administration compared to the control group (2.9 ± 1.1% versus -0.6 ± 1.0%, P = 0.034). HCEt significantly improved the CVR 2 hours after administration compared to the historical control group (9.1 ± 4.0% versus -8.1 ± 4.1%, P = 0.007). The mean blood pressure and pulse rate did not vary from baseline values in either group. Conclusions. We demonstrated that HCEt improved erythrocyte deformability and CVR. Our findings suggest that an improvement in erythrocyte deformability contributes to HCEt's effect on cerebral microcirculation.

No MeSH data available.


Related in: MedlinePlus